Spotlight On... Philips looks to add India health tech venture fund to existing ones in Israel, Netherlands; Diabetes app player Sweetch crowdfunds $3.5M with Philips participation; TearScience raises Series D; and more...

Royal Philips ($PHG) is looking to invest globally in venture efforts to support healthcare technology startups. Its latest could be slated for India, the company's Jeroen Tas, who heads Philips Connected Care and Health Informatics, told The Economic Times. The company already has an existing venture fund in the Netherlands, as well as Israeli funds including a roughly $30 million joint effort with Teva Pharmaceuticals ($TEVA). More

@FierceMedDev: IBM and Pfizer join forces for real-time patient monitoring system for Parkinson's. Article | Follow @FierceMedDev

@EmilyWFierce: UPDATED: FDA nitpicks Shionogi's head lice copay voucher over 'false and misleading' claims. More from FiercePharmaMarketing | Follow @EmilyWFierce

> Diabetes prevention app company Sweetch Health has crowdfunded a $3.5 million Series A financing with participation from Royal Philips ($PHG). Article

> Meibomian gland dysfunction device company TearScience has raised an undisclosed amount in a Series D financing to support its marketed products. Its last SEC-disclosed round was almost $40 million in 2010. More

> Israeli startup Livia has started a $50,000 Indiegogo crowdfunding campaign to back its gel-pad based device to use electrical stimulation to treat menstrual cramps. More

Biotech News

@FierceBiotech: EuroBiotech Report: Big Pharma trio backs cancer startup; AB jumps on ALS data; Shire founder oversees AIM listing. More | Follow @FierceBiotech

@JohnCFierce: FDA reviewers question efficacy, raise safety issues and cite a challenge on Clovis's rociletinib. Article | Follow @JohnCFierce

> After ZS Pharma buyout, Relypsa slated to be next on the hit list. Story

> AstraZeneca, Eli Lilly move closely watched BACE Alzheimer's trial into PhIII. Report

> MedDay raises $38.5M to fund PhIII push for its multiple sclerosis drug. Article

Pharma News

@FiercePharma: Taiwan research head apologizes as he admits selling off OBI Pharma shares. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Unable to find a buyer, Sun will close the Ranbaxy plant in Ireland, lay off 70 remaining workers. Article | Follow @EricPFierce

@CarlyHFierce: Ironwood exec's brainstorm gives Allergan a marketing edge with Linzess. FiercePharmaMarketing article | Follow @CarlyHFierce

> Buyers eye Relypsa and its hyperkalemia drug. Article

> Hedge fund aims to oust Depomed board for 'troubling record.' Story

> Novo makes inroads in Japan with long-acting insulin Tresiba. News